← All trials
NCT04478500
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 15, 2020
- Primary completion
- Aug 1, 2022
- Completion date
- Feb 1, 2023
- First posted
- Jul 20, 2020
- Last posted
- Oct 8, 2020
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Western AustraliaLead sponsor
- University of Western AustraliaReponsible party - principal investigator
- University of Western AustraliaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.